Skip to main content
. 2024 Aug 15;16(8):3481–3495. doi: 10.4251/wjgo.v16.i8.3481

Figure 1.

Figure 1

The illustrated flowchart of selecting patient for comparing between camrelizumab plus apatinib and hepatic artery infusion chemotherapy alone and camrelizumab plus apatinib and hepatic artery infusion chemotherapy combined with microwave ablation treatment in patients with advanced hepatocellular carcinoma. HCC: Hepatocellular carcinoma; MWA: Microwave ablation; TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; SR: Liver resection surgery; HAIC: Hepatic arterial infusion chemotherapy; PSM: Propensity score matching.